Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 163

1.

The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial.

Obońska K, Kasprzak M, Sikora J, Obońska E, Racki K, Goździkiewicz N, Krintus M, Kubica J.

Trials. 2017 Jul 11;18(1):316. doi: 10.1186/s13063-017-2047-8.

2.

Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a).

Vavlukis M, Mladenovska K, Daka A, Dimovski A, Domazetovska S, Kuzmanovska S, Kedev S.

Ann Pharmacother. 2016 Aug;50(8):609-15. doi: 10.1177/1060028016652415. Epub 2016 May 30.

PMID:
27242350
3.

Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect.

Hörl G, Froehlich H, Ferstl U, Ledinski G, Binder J, Cvirn G, Stojakovic T, Trauner M, Koidl C, Tafeit E, Amrein K, Scharnagl H, Jürgens G, Hallström S.

PLoS One. 2016 Feb 3;11(2):e0148210. doi: 10.1371/journal.pone.0148210. eCollection 2016.

4.

The association of HDL-apoCIII with coronary heart disease and the effect of statin treatment on it.

Xiong X, Liu H, Hua L, Zhao H, Wang D, Li Y.

Lipids Health Dis. 2015 Oct 9;14:127. doi: 10.1186/s12944-015-0129-8.

5.

Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk.

Rosen JB, Ballantyne CM, Hsueh WA, Lin J, Shah AK, Lowe RS, Tershakovec AM.

Lipids Health Dis. 2015 Sep 4;14:103. doi: 10.1186/s12944-015-0075-5.

6.

Lipid parameters in patients with acute coronary syndromes versus stable coronary artery disease.

Vonbank A, Saely CH, Rein P, Drexel H.

Eur J Clin Invest. 2015 Oct;45(10):1092-7. doi: 10.1111/eci.12513. Epub 2015 Sep 13.

PMID:
26255620
7.

Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial.

Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby JF, Tricoci P, White H, Zeiher A, Steg PG.

Am Heart J. 2014 Nov;168(5):682-9. doi: 10.1016/j.ahj.2014.07.028. Epub 2014 Aug 7.

8.

Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.

Puri R, Nissen SE, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Libby P, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ.

Arterioscler Thromb Vasc Biol. 2014 Nov;34(11):2465-72. doi: 10.1161/ATVBAHA.114.303932. Epub 2014 Sep 11.

9.

Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides.

Prenner SB, Mulvey CK, Ferguson JF, Rickels MR, Bhatt AB, Reilly MP.

Atherosclerosis. 2014 Oct;236(2):244-50. doi: 10.1016/j.atherosclerosis.2014.07.008. Epub 2014 Jul 22.

10.

Relation of high-density lipoprotein cholesterol:apolipoprotein a-I ratio to progression of coronary atherosclerosis in statin-treated patients.

Mani P, Uno K, St John J, Tuzcu EM, Nissen SE, Nicholls SJ.

Am J Cardiol. 2014 Sep 1;114(5):681-5. doi: 10.1016/j.amjcard.2014.06.001. Epub 2014 Jun 18.

PMID:
25030535
11.

Which lipid measurement should we monitor? An analysis of the LIPID study.

Glasziou PP, Irwig L, Kirby AC, Tonkin AM, Simes RJ.

BMJ Open. 2014 Feb 21;4(2):e003512. doi: 10.1136/bmjopen-2013-003512.

13.

Therapeutic approaches to the regulation of metabolism of high-density lipoprotein. Novel HDL-directed pharmacological intervention and exercise.

Zhang B, Kawachi E, Miura S, Uehara Y, Matsunaga A, Kuroki M, Saku K.

Circ J. 2013;77(11):2651-63. Epub 2013 Oct 10. Review.

14.

The influence of statin-fibrate combination therapy on lipids profile and apolipoprotein A5 in patients with acute coronary syndrome.

Li XP, Gong HR, Huang XS, Huang WY, Zhao SP.

Lipids Health Dis. 2013 Sep 9;12:133. doi: 10.1186/1476-511X-12-133.

15.

High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy.

Mora S, Glynn RJ, Ridker PM.

Circulation. 2013 Sep 10;128(11):1189-97. doi: 10.1161/CIRCULATIONAHA.113.002671. Epub 2013 Sep 3.

16.

Stabilization of atherosclerotic plaques: an update.

Ylä-Herttuala S, Bentzon JF, Daemen M, Falk E, Garcia-Garcia HM, Herrmann J, Hoefer I, Jauhiainen S, Jukema JW, Krams R, Kwak BR, Marx N, Naruszewicz M, Newby A, Pasterkamp G, Serruys PW, Waltenberger J, Weber C, Tokgözoglu L; ESC Working Group of Atherosclerosis and Vascular Biology.

Eur Heart J. 2013 Nov;34(42):3251-8. doi: 10.1093/eurheartj/eht301. Epub 2013 Aug 21. No abstract available.

PMID:
23966311
17.

Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.

18.

Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.

PMID:
23932901
19.

New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.

Sahebkar A, Watts GF.

Clin Ther. 2013 Aug;35(8):1082-98. doi: 10.1016/j.clinthera.2013.06.019. Epub 2013 Aug 8. Review.

PMID:
23932550
20.

Comparison of pitavastatin with atorvastatin in increasing HDL-cholesterol and adiponectin in patients with dyslipidemia and coronary artery disease: the COMPACT-CAD study.

Kurogi K, Sugiyama S, Sakamoto K, Tayama S, Nakamura S, Biwa T, Matsui K, Ogawa H; COMPACT-CAD Investigators.

J Cardiol. 2013 Aug;62(2):87-94. doi: 10.1016/j.jjcc.2013.03.008. Epub 2013 May 11.

Supplemental Content

Loading ...
Support Center